Research published in the Journal of Translational Medicine, Frontiers in Neurology and Frontiers in Neuroscience journals finds oxaloacetate improves ME/CFS and Long COVID symptoms including physical fatigue, mental fatigue, cognition, symptom burden and upright activity. SAN DIEGO, Calif. — August 2026 — Terra Biological today highlighted the substantial and growing body of clinical evidence…
A new pilot study has added to the growing evidence that the immune system may play an important role in ME/CFS for some patients. Researchers investigated daratumumab, a medication that targets long-lived plasma cells, the immune cells responsible for producing antibodies. Their hypothesis is that, in a subgroup of people with ME/CFS, these plasma cells may produce harmful autoantibodies that…
SAN DIEGO, Calif. — June 2026 — Terra Biological LLC today announced that eligible customers can now seamlessly use Health Savings Account (HSA) and Flexible Spending Account (FSA) funds to purchase Oxaloacetate CFS™ , a medical food clinically proven to lower fatigue in patients with Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). For the millions of individuals living…
A recent article in the Annals of Family Medicine highlights an important issue for people living with ME/CFS: many potentially helpful treatment options remain underused in general medical care. The study reviewed records from 571 patients with ME/CFS who were referred to a specialty clinic between 2018 and 2022. Researchers found that, outside of medications commonly used for pain and anxiety,…
Last week, the Oxaloacetate CFS team traveled to England to attend the 18th International ME Conference, organized by Invest in ME Research at the Wellcome Genome Campus. The conference brought together researchers, clinicians, patient advocates, and members of the ME/CFS community from around the world to share the latest developments in research and clinical care. What makes International ME…
The Oxaloacetate CFS team is heading to England for the 18th International ME Conference 2026 hosted by Invest in ME Research, and after reviewing this year’s agenda, we’re more excited than ever about the direction ME/CFS research is heading. A Strong Focus on Clinical Trials and Real-World Treatments One of the major themes throughout the conference is the push toward structured clinical trials…
At Oxaloacetate CFS, one of the most rewarding parts of our work is connecting directly with the clinicians, researchers, and patients who are dedicated to advancing the understanding of ME/CFS. This past month has been especially meaningful for our team as we’ve attended three major conferences focused on complex chronic illness, mitochondrial health, and emerging treatment approaches for ME/CFS.…
At the start of May, the Oxaloacetate CFS team traveled to Berlin for the International ME/CFS Conference, where we had the opportunity to present our latest research poster in the conference’s “Clinical Studies” poster group. Our poster, titled “Relationships between fatigue, cognitive function and upright activity in a randomized trial of Oxaloacetate for myalgic encephalomyelitis/chronic…
Oxaloacetate CFS will be attending the International ME/CFS Conference 2026 , taking place on 7–8 May 2026 as a hybrid scientific event broadcast from Berlin, Germany. Hosted at the Harnack House and organised under the leadership of the Carmen Scheibenbogen at Charité – Universitätsmedizin Berlin, the conference brings together international experts working on ME/CFS and post-COVID syndrome. The…
Alan Cash Appears on Dr. Robert G. Silverman Podcast to Discuss Oxaloacetate Research in ME/CFS and Post-COVID Conditions Alan Cash, CEO and Chief Science Officer of Terra Biological LLC, recently appeared as a guest on the podcast hosted by Robert G. Silverman to discuss emerging research on oxaloacetate and its potential applications in chronic illness, aging, and metabolic health. Watch the…
